AustriaAustria

Bioventis Focus' on Novel Antibiotics

23.11.2003

Vienna -Austria's Intercell AG has founded its first spin-off, Biovertis Information Driven Drug Design AG. Intercell is a privately held company, which focuses on the development of vaccines against infectious diseases. The decision to spin off its pipeline research department was prompted by the discovery that one of the company's platform technologies, Antigen Identification Program (AIP), can also be used to develop novel antibiotics.
Intercell will retain its focus on vaccines, while the new company will be free to exploit the full potential of the new application. The parent company has seen Bio-ventis getting a good start by financing the preparation of its R&D programme and business plan. It has recruited its core team from Intercell, including CSO Dr. Uwe von Ahsen. Outlining the strategy, von Ahsen said: “Our goal is to develop new antibio-tics against bacteria that are resistant to existing antibiotic treatments and cause diseases such as respiratory ailments or sepsis.” The company has a close working relationship with the University of Vienna.

AustriaAustria

03.11.2010

Austrian vaccine developer Intercell AG (Vienna) has a new Chief Business Officer. At the beginning of October, Staph Leavenworth Bakali quit Intercell’s supervisory board and joined its management board with key responsibilities...

AustriaAustria

03.11.2010

Vienna – Austrian vaccine specialist Intercell AG has landed a new partner for its therapeutic vaccine IC41 against chronic infections with the hepatitis C virus (HCV) after Novartis quit a a 270m partnership with the firm this...

AustriaAustria

16.09.2010

Bremen/Vienna/Galway – A novel protein glue that helps colonies of the barnacle Dosima fascicularis to float on the surface of the water and stick to vessels could inspire the next revolution in medicine and material sciences....

AustriaAustria

18.08.2010

Vienna – Austrian vaccine specialist Intercell AG increased R&D spending by 24% in the second quarter of 2010 to EUR16.9m due to expenditures linked to clinical Phase III testing of its traveller's diarrhoea vaccine. That...

AustriaAustria

19.07.2010

An estimated 20,000 participants from over 185 countries are taking part in the 18th International AIDS Conference that began in Vienna on Sunday. The head of the International AIDS Society, and conference chairman, Julio...

AustriaAustria

14.07.2010

Vienna – Swissmedic has approved IXIARO®, a vaccine against Japanese encephalitis from Intercell AG that is distributed and marketed by Novartis AG. The decision by the Swiss authorities is another important milestone for the...

AustriaAustria

10.07.2010

Vienna – Austria’s Intercell AG has closed the acquisition of Cytos’ platform technology for monoclonal antibody discovery, which is based on expression cloning of monoclonal antibodies from human B-cells. As per agreed terms,...

AustriaAustria

12.05.2010

Vienna – Invoking the EU’s safeguard clause, the Austrian parliament has unanimously instructed its Ministry of Health to establish a specific legal measure to prohibit the cultivation of the biotech potato Amflora in the...

AustriaAustria

07.05.2010

Vienna – Austrian Intercell AG expands its current vaccine business to anti-infective monoclonal antibodies. In a EUR 15 million deal Intercell has bought Cytos' antibody discovery platform technology, the firm announced on 6th...

Displaying results 21 to 30 out of 116

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/2/article/bioventis-focus-on-novel-antibiotics.html

Print Magazine

Product of the week

Products

Events

All Events

Partner-Events

Stock list

All quotes

TOP

  • FORMYCON9.74 EUR9.44%
  • CYTOS0.29 CHF3.57%
  • BAYER118.00 EUR3.42%

FLOP

  • MAGFORCE6.12 EUR-2.55%
  • SARTORIUS95.00 EUR-2.06%
  • ADDEX3.01 CHF-1.95%

TOP

  • CYTOS0.29 CHF81.2%
  • EPIGENOMICS5.25 EUR48.7%
  • STRATEC BIOMEDICAL48.65 EUR25.2%

FLOP

  • BIOFRONTERA2.53 EUR-12.8%
  • ADDEX3.01 CHF-8.8%
  • CO.DON2.53 EUR-8.0%

TOP

  • SANTHERA91.30 CHF2585.3%
  • CO.DON2.53 EUR141.0%
  • BB BIOTECH182.60 EUR64.6%

FLOP

  • CYTOS0.29 CHF-91.5%
  • 4SC0.94 EUR-46.0%
  • MOLOGEN7.39 EUR-41.1%

No liability assumed, Date: 23.11.2014

Current issue

All issues